NR3C2 and chronic kidney disease: Furthermore, both guidelines suggest that non-steroidal mineralocorticoid receptor antagonists (such as finerenone) may be an effective option for patients with CKD who are at high risk of cardiovascular events, CKD progression, or cannot tolerate SGLT2is [30, 31].